P2-6-3 - A Retrospective Study of Weekly Paclitaxel as Second-Line Treatment for Advanced or Recurrent Esophageal Cancer

Abstract

Background: Docetaxel and Paclitaxel have been used for advanced or recurrent esophageal cancer who failed first-line chemotherapy. However, standard chemotherapy as second-line setting has not been established.Objectives: To evaluate Paclitaxel by weekly infusion for advanced or recurrent esophageal cancer in second-line setting.Patients and methods: The subjects of this study were 13 patients treated with Paclitaxel from October 2012 to December 2013 at Hyogo Cancer Center. We retrospectively evaluated patient characteristics, response, survival, and toxicity.Results: Median age:62 (47-76), Male/Female:12/1, PS 0/1/2:5/7/1, Advanced/recurrent:3/10, metastatic sites lymph node/lung/liver/others:11/3/1/3, the number of metastatic sites 0/1/2:1/7/5, prior therapy surgery/chemo-radiotherapy/ chemotherapy:6/9/4, and the all patients had Squamous cell carcinoma. The mean number of the course was 2.7. The overall response rate was 37%(3/8), the median progression-free survival was 3.7 months and the median survival time was 7.3 months. As for the grade 3/4 hematological toxicities, the incidences of WBC, ANC and anemia were 23%, 46% and 7%. As for the grade 3/4 non-hematological toxicities, anorexia was 7%, and febrile neutropenia was 7%. There were no treatment-related deaths.Conclusion: weekly Paclitaxel was tolerable as second-line treatment for advanced or recurrent esophageal cancer